ABBV Nov 2023 155.000 put
| Previous close | 19.55 |
| Open | 21.55 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 155.00 |
| Expiry date | 2023-11-17 |
| Day's range | 19.55 - 21.55 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Motley FoolWhy AbbVie and Amgen Are Moving Lower Today
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. Coherus' biosimilar will be branded as Yusimry.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Motley Fool2 Dividend Kings on Sale That Are Yielding More Than 4%
Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). Healthcare company AbbVie pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%.
Motley Fool2 Top Dividend Kings to Buy for the Long Haul
Last year revealed the importance of having safe stocks in your portfolio during times of market volatility. Enter dividend stocks. What's better than companies that have a track record of consistently paying and increasing dividends?
ZacksThe Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.
ZacksTop Research Reports for AbbVie, Intel & Qualcomm
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).
ZacksIronwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
ZacksAbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
ReutersIronwood bulks up on digestive therapies with $1.15 billion VectivBio buy
(Reuters) -Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its portfolio. Ironwood has offered $17 per share for VectivBio, a premium of about 43% to the stock's last close. VectivBio's shares were at $16.21 in morning trade, while Ironwood's stock fell 4.5% to $10.
Motley Fool3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
Motley Fool3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now
This condition can easily occur when selecting dividend stocks. Here are three no-brainer dividend stocks to buy with $1,000 right now. Brookfield Renewable Partners (NYSE: BEP) (NYSE: BEPC) offers a distribution yield of over 4.2% for its limited partnership shares (traded under the BEP ticker) and over 3.8% for its corporate shares (traded under the BEPC ticker).
ZacksAbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
- Zacks
Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
ZacksAbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Investing.com
Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: new data from X4 Pharma, upcoming review dates for Krystal Biotech, and a torrent of news set for release at an annual biotech conference.
CNW GroupHealth Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
AbbVie (NYSE: ABBV), today announced that Health Canada has approved RINVOQ® (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable.
Motley Fool1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now
If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. Despite its fully expected, yet ultimately abysmal, first-quarter earnings, the 1% total return of its shares over the last 12 months is still above and beyond the 4% loss for the SPDR S&P 500 ETF Trust, the ETF tracking the S&P 500 index. Here's why AbbVie can do it, and why it could be a smart investment for long-term holding.
Motley FoolLooking for Steady, Passive Income? Buy AbbVie Stock
Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth. With 51 consecutive years of dividend growth to its credit (including time spent as part of Abbott Laboratories), AbbVie (NYSE: ABBV) certainly has such a record.
Motley Fool3 Great Income Stocks That Retirees Should Love
If you're looking for additional retirement income, these three stocks should be right up your alley.
ZacksIronwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
Motley Fool2 Things About AbbVie That Investors Are Ignoring
Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter sales wasn't a surprise.
Motley FoolHere's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock
Had you bought Vertex Pharmaceuticals (NASDAQ: VRTX) shares 10 years ago, you'd be sitting pretty right now. The drugmaker soundly outperformed the market over that period thanks to its success in developing medicines that target cystic fibrosis. The first of Vertex's products to treat that rare genetic disease was approved in 2012.
Motley FoolVertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment. The company is known for its combination therapies targeting a defective protein that causes the disease's devastating symptoms. AbbVie (NYSE: ABBV) had shepherded its own combination-therapy candidate -- also targeting the defective protein -- into phase 2 studies.
Motley Fool3 of the Best High-Yielding Dividend Stocks to Buy in May
These dividend stocks are trading at cheap prices, and long-term investors should consider buying them right now.